These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 34793279)

  • 1. Prostaglandin-associated periorbitopathy syndrome (PAPS): Addressing an unmet clinical need.
    Sakata R; Chang PY; Sung KR; Kim TW; Wang TH; Perera SA; Cantor LB
    Semin Ophthalmol; 2022 May; 37(4):447-454. PubMed ID: 34793279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Patient Tolerability of Omidenepag Isopropyl in the Treatment of Glaucoma and Ocular Hypertension.
    Matsuo M; Matsuoka Y; Tanito M
    Clin Ophthalmol; 2022; 16():1261-1279. PubMed ID: 35510270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Additive Intraocular Pressure-Lowering Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, Combined with Existing Antiglaucoma Agents in Conscious Ocular Normotensive Monkeys.
    Fuwa M; Shimazaki A; Odani-Kawabata N; Kirihara T; Taniguchi T; Iwamura R; Yoneda K; Kato M; Morishima K; Shams NK
    J Ocul Pharmacol Ther; 2021 May; 37(4):223-229. PubMed ID: 33600237
    [No Abstract]   [Full Text] [Related]  

  • 4. Intraocular pressure-lowering effect of omidenepag isopropyl in latanoprost non-/low-responder patients with primary open-angle glaucoma or ocular hypertension: the FUJI study.
    Aihara M; Ropo A; Lu F; Kawata H; Iwata A; Odani-Kawabata N; Shams N
    Jpn J Ophthalmol; 2020 Jul; 64(4):398-406. PubMed ID: 32572719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interim Results of Post-Marketing Observational Study of Omidenepag Isopropyl for Glaucoma and Ocular Hypertension in Japan.
    Nakazawa T; Takahashi K; Kuwayama Y; Nomura A; Shimada F
    Adv Ther; 2022 Mar; 39(3):1359-1374. PubMed ID: 35072890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostaglandin-Associated Periorbitopathy Symptom Alleviation After Switching Prostaglandin F Receptor Agonist to EP2 Receptor Agonist in Patients with Glaucoma.
    Sakata R; Fujishiro T; Saito H; Nakamura N; Honjo M; Shirato S; Miyamoto E; Yamada Y; Aihara M
    J Ocul Pharmacol Ther; 2023; 39(1):63-69. PubMed ID: 36318495
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacologic Characterization of Omidenepag Isopropyl, a Novel Selective EP2 Receptor Agonist, as an Ocular Hypotensive Agent.
    Kirihara T; Taniguchi T; Yamamura K; Iwamura R; Yoneda K; Odani-Kawabata N; Shimazaki A; Matsugi T; Shams N; Zhang JZ
    Invest Ophthalmol Vis Sci; 2018 Jan; 59(1):145-153. PubMed ID: 29332128
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    DI Staso S; Agnifili L; Cecannecchia S; DI Gregorio A; Ciancaglini M
    In Vivo; 2018; 32(2):211-220. PubMed ID: 29475902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Twelve-month efficacy and safety of omidenepag isopropyl, a selective EP2 agonist, in open-angle glaucoma and ocular hypertension: the RENGE study.
    Aihara M; Lu F; Kawata H; Iwata A; Odani-Kawabata N
    Jpn J Ophthalmol; 2021 Nov; 65(6):810-819. PubMed ID: 34495425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of early medication persistence with omidenepag isopropyl, a topical selective prostaglandin EP2 agonist, in patients with glaucoma: a retrospective two-institute study.
    Nakakura S; Kanamori A; Fukuma Y; Wakabayashi S; Nagata Y; Adachi M
    BMJ Open; 2021 Jan; 11(1):e040301. PubMed ID: 33514572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys.
    Fuwa M; Toris CB; Fan S; Taniguchi T; Ichikawa M; Odani-Kawabata N; Iwamura R; Yoneda K; Matsugi T; Shams NK; Zhang JZ
    J Ocul Pharmacol Ther; 2018 Sep; 34(7):531-537. PubMed ID: 29989843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl.
    Iwamura R; Tanaka M; Okanari E; Kirihara T; Odani-Kawabata N; Shams N; Yoneda K
    J Med Chem; 2018 Aug; 61(15):6869-6891. PubMed ID: 29995405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Omidenepag isopropyl for the treatment of glaucoma and ocular hypertension.
    Ferro Desideri L; Cutolo CA; Barra F; Ferrero S; Traverso CE
    Drugs Today (Barc); 2019 Jun; 55(6):377-384. PubMed ID: 31250842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostaglandin associated periorbitopathy in patients using bimatoprost, latanoprost and travoprost.
    Kucukevcilioglu M; Bayer A; Uysal Y; Altinsoy HI
    Clin Exp Ophthalmol; 2014 Mar; 42(2):126-31. PubMed ID: 23844550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Staging of Prostaglandin-Associated Periorbitopathy Syndrome in Glaucoma: A Review from Asia.
    Liu C; Wong T; Leung D; Park HL; Aung T; Aihara M; Makornwattana M; Fang SK; Park KH; Leung C
    Semin Ophthalmol; 2024 Jun; ():1-5. PubMed ID: 38842062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics, Safety, and Intraocular Pressure-Lowering Profile of Omidenepag Isopropyl, a Selective, Nonprostaglandin, Prostanoid EP2 Receptor Agonist, in Healthy Japanese and Caucasian Volunteers (Phase I Study).
    Aihara M; Lu F; Kawata H; Tanaka Y; Yamamura K; Odani-Kawabata N; Shams NK
    J Ocul Pharmacol Ther; 2019 Dec; 35(10):542-550. PubMed ID: 31674861
    [No Abstract]   [Full Text] [Related]  

  • 17. Phase 2, Randomized, Dose-finding Studies of Omidenepag Isopropyl, a Selective EP2 Agonist, in Patients With Primary Open-angle Glaucoma or Ocular Hypertension.
    Aihara M; Lu F; Kawata H; Iwata A; Liu K; Odani-Kawabata N; Shams NK
    J Glaucoma; 2019 May; 28(5):375-385. PubMed ID: 30839416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Omidenepag Isopropyl Versus Latanoprost in Primary Open-Angle Glaucoma and Ocular Hypertension: The Phase 3 AYAME Study.
    Aihara M; Lu F; Kawata H; Iwata A; Odani-Kawabata N; Shams NK
    Am J Ophthalmol; 2020 Dec; 220():53-63. PubMed ID: 32533949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. One-Year Follow-Up Study of Changes in Prostaglandin-Associated Periorbital Syndrome After Switch From Conventional Prostaglandin F2alfa to Omidenepag Isopropyl.
    Oogi S; Nakakura S; Terao E; Fujisawa Y; Tabuchi H; Kiuchi Y
    Cureus; 2020 Aug; 12(8):e10064. PubMed ID: 33005498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new look at the safety and tolerability of prostaglandin analogue eyedrops in glaucoma and ocular hypertension.
    Katsanos A; Riva I; Bozkurt B; Holló G; Quaranta L; Oddone F; Irkec M; Dutton GN; Konstas AG
    Expert Opin Drug Saf; 2022 Apr; 21(4):525-539. PubMed ID: 34666576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.